Alzheimer’s researchers are hoping for a breakthrough with a new targeted approach to preventing disease progression in certain people with the disease.
Neurology specialist Alzheon has been awarded a $47 million grant, over five years, to support a Phase III study with ALZ-801, an oral agent that blocks the formation of the amyloid proteins implicated in the pathology of the condition.